Skip to main content
Clinical Trials/NCT03580954
NCT03580954
Completed
Not Applicable

Transcranial Magnetic Stimulation in Primary Progressive Aphasia

Hospital San Carlos, Madrid1 site in 1 country20 target enrollmentFebruary 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Progressive Aphasia
Sponsor
Hospital San Carlos, Madrid
Enrollment
20
Locations
1
Primary Endpoint
Changes in reading
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurodegeneration of language brain systems. Three main clinical variants are currently recorgnized (nonfluent, semantic, and logopenic PPA). Nowadays, there are no effective treatments for this disorder.

Transcranial Magnetic Stimulation (TMS) is a technique based on the principle of electromagnetic induction of an electric field in the brain. It has been used as a non-invasive therapy in different disorders, such as depression, bipolar disorder, Parkinson's disease, and in the rehabilitation of post-stroke aphasia. Recent studies have shown how repetitive TMS improved language characteristics in Alzheimer's disease, and there are initial data in patients with PPA.

This research project investigates the effect of repetitive TMS in patients with PPA. Investigators will perform a personalized TMS treatment for each patient (brain region, type of stimulation/inhibition, etc.), according to the specific characteristics of each patient and with the final aim to generate a computational model.

Registry
clinicaltrials.gov
Start Date
February 1, 2018
End Date
March 10, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jordi A Matias-Guiu

Principal Investigator. PhD MD

Hospital San Carlos, Madrid

Eligibility Criteria

Inclusion Criteria

  • Must be clinically diagnosed of PPA according to current diagnostic criteria (Gorno-Tempini et al. 2011) with PET-FDG confirmation.
  • Clinical Dementia Rating 0-1.

Exclusion Criteria

  • Contraindications for TMS or MRI
  • History of epilepsy
  • Pregnancy
  • Other language disorder previous to the diagnosis of PPA
  • Neuroimaging not suggestive of PPA

Outcomes

Primary Outcomes

Changes in reading

Time Frame: 2 months

Story and words reading test

Changes in spontaneous speech (main primary endpoint)

Time Frame: 2 months (at baseline and at the end of the treatment)

Picture and story description task

Changes in oral naming

Time Frame: 2 months

Object naming test

Changes in repetition

Time Frame: 2 months (at baseline and at the end of the treatment)

Non-words and sentence repetition task

Secondary Outcomes

  • Changes in brain metabolism(2 months (at baseline and at the end of the treatment))
  • Changes in brain cortical electrical activity(2 months (at baseline and at the end of the treatment))
  • Changes in clinical impression of change(2 months)
  • Changes in global cognition(2 months (at baseline and at the end of the study))

Study Sites (1)

Loading locations...

Similar Trials